Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About its Expanded DehydraTECH Investigations; Plans for More Studies in 2022
Lexaria just announced ground-breaking findings from its recently-concluded Sildenafil animal study The success of this study sets the stage for various other studies on the use of the company’s patented DehydraTECH technology The company is set to commence dosing its most extensive hypertension study in April 2022, with results expected in Q3 2022 Its successful completion could greatly enhance Lexaria’s leadership position in the global drug delivery market Lexaria Bioscience (NASDAQ: LEXX) kicked off the 2022 calendar year by receiving independent review board approval for its upcoming DehydraTECH(TM)-CBD human hypertension study, HYPER-H21-4. Additionally, in what marks another critical milestone, the…